Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Over the past 15 years or more there has been a move to more aggressive, disease-modifying drug treatment early in the course of juvenile idiopathic arthritis (JIA). In 1998 researchers in Holland (M A van Rossum and colleagues. Annals of Rheumatic Diseases 2007;66:1518–24) reported the results of a 24-week placebo-controlled trial of sulfasalazine for children with JIA of oligoarticular or …